Market Research Logo

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Summary


Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

Hypertension itself does not manifest any symptoms, but direct damage can occur to various organs due to high blood pressure. In cases of hypertensive emergency (where blood pressure is higher than 180/110mmHg) patients have reported headaches, breathlessness or malaise due to heart failure and kidney failure. Whether symptomatic or asymptomatic, hypertension requires attention and appropriate changes in lifestyle or medical treatment

The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.

The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.

Scope

The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.

      
  • Will generics continue to dominate treatment?
  •  
  • How do the elderly populations and their associated risk factors affect prevalence?
  •  
  • What effect will the patent expirations of currently branded therapies have on market value?
The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.
     
  • Which molecular targets appear most frequently in the pipeline?
  •  
  • Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
     
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  •  
  • How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.
     
  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
  •  
  • How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?
  •  
  • Various drivers and barriers will influence the market over the forecast period.
  •  
  • What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
  •  
  • Which factors are most likely to drive the market in these countries?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals.


Asia-Pacific anti-hypertensive therapeutics market to hit $27 billion by 2022, despite low innovation, says GBI Research

The market for anti-hypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea, and Japan, is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%, according to business intelligence provider GBI Research.

The company’s latest report states that this relatively solid rise in market value will be driven by the increasingly elderly population – where the prevalence rate of hypertension is highest – and increases in risk factors such as obesity, low physical activity levels, urbanization, and smoking. Indeed, growth will not be aided by the weak anti-hypertensive pipeline, due to lack of innovative products in late-stage development.

Gautam Arora, Analyst for GBI Research, explains: “The anti-hypertensive pipeline consists of 112 pipeline products, most of which are small molecules. The limited presence of other types of molecules in the pipeline suggests that large pharmaceutical companies are refraining from developing novel molecules and are more inclined to focus on patient-compliant combination therapies. It is therefore unlikely that any completely novel molecules will enter the market during the forecast period.

“Prestalia is an example of a recently improved drug that offers an improvement to hypertension therapy. In a Phase III trial it provided a better benefit-to-risk ratio than either treatment alone. The drug was approved by the US FDA in January 2015, and it is marketed by Symplmed. Of the APAC countries covered in the report, however, it is available only in Australia, and it is under development in Japan and South Korea.”

Overall, late-stage products will not change the treatment paradigm of hypertension during the forecast period. With the lack of any new premium-priced drugs in this setting and the prescription of relatively cheap generic versions of anti-hypertensive drugs to continue, GBI Research expects the status quo of drug treatment to persist in the APAC region.

Arora concludes: “Despite the availability of a large number of blood-pressure-lowering agents, the need remains for safer and more effective anti-hypertensive treatments. Although the APAC market is likely to see steady growth, it will continue to be obstructed by a weak pipeline and low diagnosis and treatment rates.

“Indeed, the asymptomatic nature of the disease along with a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China can limit diagnosis rates.”

- Comments provided by Gautam Arora, Analyst for GBI Research.
- Information based on GBI Research’s report: “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline”.
- This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.5.1 Office or Clinic Blood Pressure Monitoring
2.5.2 Automated Office Blood Pressure Measurement
2.5.3 Ambulatory Blood Pressure Monitoring
2.5.4 Home Blood Pressure Monitoring
2.5.5 Miscellaneous Methods
2.5.6 Diagnosis of Target Organ Damage
2.5.7 Diagnosis of Hypertension in Pregnancy
2.6 Prognosis
2.7 Disease Stage
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Pharmacological Treatment
2.8.3 Non-pharmacological Treatment
3 Marketed Products
3.1 Angiotensin II Receptor Antagonists
3.1.1 Losartan - Merck & Co
3.1.2 Olmesartan - Daiichi Sankyo
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo
3.1.4 Valsartan - Novartis
3.1.5 Telmisartan - Boehringer Ingelheim
3.1.6 Azilsartan Medoxomil - Takeda
3.2 Calcium Channel Blockers
3.2.1 Amlodipine - Pfizer
3.3 Renin Inhibitors
3.3.1 Aliskiren - Novartis
3.4 Angiotensin Converting Enzyme Inhibitors
3.4.1 Ramipril - Sanofi
3.5 Beta Blockers
3.5.1 Carvedilol - GlaxoSmithKline
3.6 Multiple Drug Class Combinations
3.6.1 Perindopril Arginine + Amlodipine Besylate - Les Laboratoires Servier
3.6.2 Amlodipine + Valsartan - Novartis
3.7 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 CS-3150
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.4 Competitive Clinical Trials Metrics Analysis
6 Multi-Scenario Forecast
6.1.1 Geographical Markets
6.1.2 Asia-Pacific Market
6.2 India
6.2.1 Treatment Use Patterns
6.2.2 Annual Cost of Therapy
6.2.3 Market Size
6.3 China
6.3.1 Treatment Use Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Australia
6.4.1 Treatment Use Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 South Korea
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Use Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Aging Populations to Increase Prevalence
7.1.2 Increasing Overweight and Obese Population
7.1.3 Increase in Daily Sodium Intake
7.1.4 Sedentary Lifestyle or Less Physical Activity
7.1.5 High Prevalence of Smoking and Alcoholism
7.1.6 Diversified Healthcare Reform to Boost Market Growth
7.2 Barriers
7.2.1 Weak Pipeline and Widespread Usage of Generic Drugs
7.2.2 Non-pharmacological First-Line Treatment
7.2.3 Lack of Awareness of the Disease Condition
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2022
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Reference
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Anti-hypertensive Therapeutics, Prevalence Rate
Table 2: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg)
Table 3: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg)
Table 4: Anti-hypertensive Therapeutics, Blood Pressure Stages in Adults (mmHg)
Table 5: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs
Table 6: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations
Table 7: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 8: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 9: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
Table 10: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 11: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase-II, 2016
Table 12: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 13: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 14: Anti-hypertensive Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 15: Anti-hypertensive Therapeutics Market, India, Market Forecast, 2015-2022
Table 16: Anti-hypertensive Therapeutics Market, China, Market Forecast, 2015-2022
Table 17: Anti-hypertensive Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 18: Anti-hypertensive Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 19: Anti-hypertensive Therapeutics Market, Japan, Market Forecast, 2015-2022
Table 20: Abbreviations
1.2 List of Figures
Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009-2012
Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin-Angiotensin-Aldosterone System
Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension
Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension
Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction
Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension
Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension
Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016
Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016
Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015
Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2015
Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015
Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015
Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2015
Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015
Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015
Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015
Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022
Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015-2022
Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015-2022
Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015-2022
Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015-2022
Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015-2022
Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015-2022
Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015-2022
Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report